# What the Latest Physiology Research Reveals About Cannabis Formulation and Diabetes Risk

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/cannabis-extract-vs-thc-metabolic-health/
> **Published:** 2026-05-14T10:14:33-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:43:17-04:00
> **Clinical Summary:** New research on cannabis and fat cells: THC cut fat mass in obese mice, but only whole-plant extract restored normal glucose clearance. What it means.

---

CED Clinical Relevance #78Strong Clinical RelevancePatients in the metabolic program ask whether cannabis affects weight and blood sugar, and the honest answer has been that nobody knows the mechanism. This study separates two effects that are usually discussed as one, and the separation is the useful part.

A preclinical study from the University of California, Riverside gave obese mice either purified THC or a whole cannabis extract matched for THC content. Both cut body weight and fat mass. Only the extract brought glucose clearance back to the level of lean animals. That split is the finding worth carrying, and it is a mouse finding.

Clinical Insight | CED Clinic

In diet-induced obese mice, both purified delta-9-tetrahydrocannabinol and whole cannabis extracts reduced body weight and fat mass, and both reversed obesity-associated changes in the expression of adipokines that regulate signaling between fat tissue and the pancreas.

The extracts did two things THC alone did not. They normalized adipokine expression more effectively, and they restored glucose clearance in obese mice to the level seen in lean animals. Losing fat and regaining glucose control turned out to be separable outcomes.

Cannabis and MetabolismAdipose TissueBlood SugarPreclinical ResearchWhole Plant vs Isolate
AudiencePatients with metabolic concerns, caregivers, and cliniciansPrimary TopicEffects of THC and whole cannabis extract on adipose tissue, adipokine signaling, and glucose control in diet-induced obesitySource[Read the full source](https://doi.org/10.1113/JP290431)
Why This Matters

The most common metabolic question patients ask about cannabis is whether it makes you gain or lose weight. That framing assumes weight is the outcome that matters. In metabolic disease, glucose handling is frequently the outcome that determines risk, and this study shows the two can move independently under the same drug.

It also puts a testable mechanism behind an epidemiological oddity that has sat unexplained for over a decade. Population surveys have repeatedly found lower obesity prevalence among frequent cannabis users despite cannabis being famous for stimulating appetite. A mouse study cannot resolve that, but it can propose where to look.

What the Experiment Did

Bryant Avalos, Martin Olmos, Courtney Wood, Camila Alvarez, Haley Read, Parima Udompholkul, Theodore Garland, and Nicholas DiPatrizio of the University of California, Riverside published the study in *The Journal of Physiology* on May 11, 2026. Garland and DiPatrizio are affiliated with the UCR Center for [Cannabinoid Research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/).

Male mice were fed either a high-fat, high-sucrose diet or a low-fat, no-sucrose diet for 60 days. At day 30, animals received either THC at 5 mg per kilogram or cannabis extracts matched for THC content, given daily for the following 30 days. The team measured adipocyte biology, glucose tolerance, insulin sensitivity, [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) expression, body weight, food intake, and motor activity.

A parallel set of experiments used 3T3-L1 cells, a standard cultured preadipocyte line, to examine what the compounds do to fat cell development and to cellular energy metabolism directly, without the confounds of appetite, activity, and whole-animal physiology.

Weight Went Down in Both Arms. Glucose Did Not.

THC and the extracts both reduced body weight and fat mass in the diet-induced obese animals. On that measure the two interventions were not meaningfully different, which is itself worth noting given how much attention THC receives as the plant’s active molecule.

Both interventions also reversed obesity-associated changes in the expression of adipokines, the signaling proteins fat tissue releases to communicate with the pancreas and other organs. The extracts did this more effectively than THC alone, a difference of degree rather than of kind.

The categorical difference appeared in glucose clearance. Extracts, but not THC, normalized glucose clearance in obese mice to levels found in lean mice. An animal can therefore lose fat on THC and still handle sugar like an obese animal. That is the result that would change how a clinician thinks about formulation if it holds up in people.

What the Adipoinsular Axis Is, and Why It Is the Right Target

The adipoinsular axis describes the two-way signaling relationship between adipose tissue and the insulin-producing beta cells of the pancreas. Fat tissue releases adipokines, including leptin and adiponectin, that influence how much insulin the pancreas secretes. The pancreas, through insulin, influences how fat tissue stores energy.

In diet-induced obesity this loop degrades. Adipokine output shifts, the pancreas receives distorted information, and insulin secretion and sensitivity drift out of alignment. That drift precedes and contributes to type 2 diabetes, which makes it a mechanistically sensible place to intervene rather than a convenient label applied after the fact.

The endocannabinoid system is embedded in both ends of that loop. CB1 receptors are expressed in adipose tissue and in pancreatic islets as well as in liver, gut, and brain. That is why cannabinoid effects on this axis are biologically plausible rather than surprising, and it is also why a single receptor-targeting molecule may behave differently from a mixture acting at several points.

The Cell Work Adds a Direct Mechanism

In 3T3-L1 cells, both THC and the extracts produced anti-adipogenic effects and altered cellular energy metabolism in a concentration-dependent manner. Anti-adipogenic means the compounds interfered with the process by which preadipocytes mature into fat-storing cells.

That matters because it removes some obvious alternative explanations. A whole animal that eats less or moves more will lose fat for reasons having nothing to do with the fat cell itself. A cultured cell line has no appetite and no exercise wheel, so an effect observed there points toward direct action on adipocyte biology.

Concentration dependence is also a useful signal. An effect that scales with dose in a controlled system behaves more like pharmacology and less like an artifact, though cultured cells are exposed to concentrations that do not map cleanly onto what reaches human adipose tissue after an oral or inhaled dose.

Where the Human Evidence Currently Sits

The epidemiological backdrop is real but limited. Yann Le Strat and Bernard Le Foll, writing in the *American Journal of Epidemiology* in 2011, analyzed two nationally representative US surveys and found adjusted obesity prevalence of 22.0% and 25.3% among adults reporting no cannabis use in the past year, compared with 14.3% and 17.2% among those using at least three days per week. Those are cross-sectional associations, not evidence that cannabis causes lower body weight.

The closest human interventional data come from a different cannabinoid. Khalid Jadoon and colleagues, in *Diabetes Care* in 2016, randomized 62 adults with non-insulin-treated type 2 diabetes across five arms for 13 weeks. Tetrahydrocannabivarin at 5 mg twice daily lowered fasting plasma glucose by an estimated treatment difference of 1.2 mmol/L and improved a measure of pancreatic beta cell function. The trial’s own primary endpoint, a change in HDL cholesterol, was not met, and the combination arms showed no significant effect.

Neither of those supports a clinical recommendation. Together they establish that the question is worth asking properly in humans, which is a lower bar than it sounds and one this field has rarely cleared.

Study SnapshotStudy TypePreclinical. Diet-induced obesity mouse model plus 3T3-L1 adipocyte cell experimentsSubjectsMale mice on high-fat/high-sucrose or low-fat/no-sucrose diet for 60 daysInterventionTHC 5 mg/kg daily, or cannabis extracts matched for THC content, from day 30 for 30 daysMeasuresAdipocyte biology, glucose tolerance, insulin sensitivity, endocannabinoid system expression, body weight, food intake, motor activityWeight ResultTHC and extracts both reduced body weight and fat mass in obese miceAdipokine ResultBoth reversed obesity-associated adipokine expression changes; extracts normalized them more effectivelyGlucose ResultExtracts, but not THC alone, normalized glucose clearance to levels found in lean miceCell ResultBoth promoted anti-adipogenic effects and altered cellular bioenergetics in 3T3-L1 cells, concentration-dependentlyInstitutionDivision of Biomedical Sciences and Center for Cannabinoid Research, University of California, RiversideJournalThe Journal of Physiology, published May 11, 2026PMID / DOI42113966 / 10.1113/JP290431
How Strong Is This Evidence?

As preclinical work this is well constructed. Matching the extracts to THC content is the design decision that makes the comparison meaningful, because it isolates the contribution of everything in the plant other than THC rather than comparing two different THC doses. Pairing whole-animal physiology with a cultured adipocyte line adds a mechanistic layer that a mouse study alone would lack.

As evidence about people it carries no weight yet, and that is not a criticism of the authors. Mice and humans differ in cannabinoid pharmacokinetics, metabolite profile, and the physiology of diet-induced obesity. The animals were male only, which leaves half the relevant biology unexamined in a field where sex differences in adipose tissue and endocannabinoid signaling are well documented.

Where This Paper Deserves Skepticism

The extracts are not chemically specified in a way that lets anyone reproduce the active ingredient. Cannabis extract is a category, not a compound. Until the responsible constituents are identified, the finding cannot be translated into a product, a dose, or a recommendation, and the authors present the identification of those constituents as work still to be done.

Male mice only. Adipose tissue distribution, adipokine secretion, and endocannabinoid tone differ by sex in both rodents and humans, and metabolic interventions have a long record of behaving differently in females. A single-sex design in metabolic research is a real limitation rather than a formality.

The 3T3-L1 concentration-response work uses exposures applied directly to cultured cells. Those concentrations do not translate simply to what circulates in a person after an oral or inhaled dose, and a concentration-dependent effect in a dish is not a dose-response curve for a patient.

What This Paper Does Not Show

This study does not show that cannabis improves blood sugar in humans. No human was studied. Extrapolating a normalized glucose clearance curve in mice to a hemoglobin A1c target in a patient is not supported by anything in this paper.

It does not identify which non-THC compounds are responsible for the difference between the extracts and purified THC. Without that, no product on any shelf can be matched to the finding, and a label reading full spectrum carries no assurance that it contains whatever did the work here.

It does not test cannabis as a treatment for obesity or type 2 diabetes, and it does not address interactions with the medications most patients with those conditions are taking. Nothing here belongs in a treatment plan.

How This Fits With the Broader Clinical Conversation

Targeting the endocannabinoid system for metabolic disease is not a new idea, and its history counsels humility. Rimonabant, a CB1 receptor blocker, produced meaningful weight loss and metabolic improvement in humans, was approved in Europe, and was withdrawn there in 2008 after psychiatric adverse effects including depression and suicidality emerged. It was never approved in the United States. The mechanism was real and the drug was unusable.

Research since has moved toward approaches that avoid central nervous system exposure or work through endogenous cannabinoid tone rather than blunt receptor blockade. Plant compounds that modulate the system without producing intoxication sit in that category, which is part of why a finding that non-THC constituents carry metabolic activity is interesting beyond the cannabis field.

The practical reading for a clinician is narrow and worth stating plainly. This work does not change what anyone should do on Monday. It does argue that the whole-plant versus isolate question, often treated as a marketing debate, has a legitimate pharmacological version that is testable and has not been tested in humans.

Dr. Caplan’s Take

The part of this study I find genuinely useful is the separation of weight loss from glucose control. Patients and clinicians both tend to treat those as the same outcome, and they are not. An intervention that reduces fat mass while leaving glucose handling impaired is doing less than it appears to be doing, and that is a distinction worth carrying into any conversation about metabolic treatment.

I want to be careful about the second part. It is tempting to read this as vindication for whole-plant preparations, and I have argued for taking formulation seriously for a long time. But this is a mouse study with an unspecified extract, in male animals only, with no human data behind it. That is a hypothesis worth funding, not a reason to choose a product.

What I tell patients in the metabolic program has not changed. If you are using cannabis, tell me, because it interacts with medications and it is relevant to how I interpret your labs. If you are asking whether to start cannabis for blood sugar, the answer is that the human evidence does not exist. This study is a reason to run the trial, not a substitute for having run it.

Clinical Bottom Line

In obese mice, purified THC and whole cannabis extract both reduced fat mass, but only the extract restored normal glucose clearance. Treat that as a mechanistic hypothesis about formulation, not as guidance. No human trial has tested a whole-plant cannabis preparation for glucose control, and nothing here should change a metabolic treatment plan.

What a Careful Reader Should Take Away

The design feature to notice is that the extracts were matched to THC content, which is what makes the comparison interpretable. The finding to carry forward is that fat loss and glucose control came apart under the same class of drug. The findings not to carry forward are any claim about humans, any claim about a specific product, and any implication that the responsible compounds have been identified. They have not.

Evidence Interpretation Guide

Table of Contents

- [How to read an animal study that separates two outcomes people usually merge](#How_to_read_an_animal_study_that_separates_two_outcomes_people_usually_merge)
- [Cannabis, Fat Cells, and Blood Sugar, Seen From Eight Angles](#Cannabis_Fat_Cells_and_Blood_Sugar_Seen_From_Eight_Angles)[Weight and blood sugar are not the same outcome](#Weight_and_blood_sugar_are_not_the_same_outcome)
- [A formulation hypothesis, not a formulation recommendation](#A_formulation_hypothesis_not_a_formulation_recommendation)
- [Cannabis extract is not a specified intervention](#Cannabis_extract_is_not_a_specified_intervention)
- [Male-only animals in metabolic research](#Male-only_animals_in_metabolic_research)
- [The epidemiology came first and stayed unexplained](#The_epidemiology_came_first_and_stayed_unexplained)
- [What to monitor in a patient already using cannabis](#What_to_monitor_in_a_patient_already_using_cannabis)
- [Name the compound, then run the trial](#Name_the_compound_then_run_the_trial)
- [The research pipeline is the bottleneck](#The_research_pipeline_is_the_bottleneck)
- [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related)

## How to read an animal study that separates two outcomes people usually merge

The Research QuestionIn diet-induced obese mice, do purified THC and whole cannabis extracts differ in their effects on fat mass, adipokine signaling, and glucose clearance?The Patient QuestionDoes cannabis affect body fat or blood sugar, and does it matter whether I use a whole-plant product or an isolate?The Bottom LineBoth reduced fat mass in mice. Only the whole extract restored glucose clearance to lean levels. Nobody has tested this in humans, and the responsible plant compounds have not been identified.
CED Perspective Lens

## Cannabis, Fat Cells, and Blood Sugar, Seen From Eight Angles

One preclinical study, read through the lenses that matter in clinical practice.

Lens OverviewObese mice received purified THC or cannabis extracts matched for THC content. Both reduced body weight and fat mass, but only the extracts normalized glucose clearance to the level of lean animals.

#### Weight and blood sugar are not the same outcome

The most useful idea in this study for a patient has nothing to do with cannabis. It is that an intervention can reduce body fat while leaving the way your body handles sugar unchanged. Weight on the scale and glucose control are related but separable, and treating them as one number hides that.

On the cannabis question specifically, this was a mouse study. It does not tell you whether a cannabis product will affect your weight or your blood sugar, and it does not identify a product to choose.

Lens takeawayDo not change anything based on this. Track glucose and fat mass as separate outcomes regardless of what you are taking.

#### A formulation hypothesis, not a formulation recommendation

The design isolates a real variable. By matching extract THC content to the purified THC dose, the investigators made everything other than THC the independent variable, and the glucose result diverged along that line while the weight result did not.

That is worth knowing when a patient asks whether whole-plant products differ from isolates. The accurate answer is that there is now a mechanistic reason to think formulation could matter metabolically, and no human data testing it.

Lens takeawayCite this as a reason to take the formulation question seriously, never as a basis for product selection.

#### Cannabis extract is not a specified intervention

The comparator here is a mixture whose active constituents remain unidentified. Two extracts from different cultivars, harvests, or extraction methods can differ substantially in minor cannabinoid and terpene content while carrying the same THC concentration.

That means the study demonstrates that something other than THC contributed, without establishing what. A reader who converts that into a claim about any commercially available full-spectrum product has gone well past the data.

Lens takeawayThe active ingredient is unknown. Until it is named, nothing here maps onto a product.

#### Male-only animals in metabolic research

Adipose distribution, adipokine secretion patterns, and endocannabinoid tone differ by sex in rodents and in people. Metabolic interventions have repeatedly behaved differently in female animals, and a single-sex design leaves that entirely unexamined.

The cultured-cell concentrations are a second interpretive limit. Exposures applied directly to 3T3-L1 cells do not correspond to plasma or tissue concentrations achieved after inhaled or oral dosing in a person.

Lens takeawaySingle-sex design and supraphysiologic cell exposures both cap how far the findings travel.

#### The epidemiology came first and stayed unexplained

Analyzing two nationally representative US surveys, Le Strat and Le Foll reported in 2011 that adjusted obesity prevalence was 22.0% and 25.3% among adults with no past-year cannabis use, versus 14.3% and 17.2% among those using at least three days per week.

That association has been cited for fifteen years without a mechanism attached to it. Its persistence is what makes a mechanistic candidate interesting, and its cross-sectional design is what keeps it from being evidence of causation.

Lens takeawayA durable association finally has a mechanistic hypothesis. The association is still not causal evidence.

#### What to monitor in a patient already using cannabis

For patients in metabolic care who use cannabis, the practical work is documentation rather than intervention. Record route, approximate dose, frequency, and product type, because those variables are what any future evidence will be indexed against.

Track fasting glucose, hemoglobin A1c, weight, and waist circumference on the schedule the underlying condition requires. Cannabis does not change that schedule, and it does not substitute for any part of it.

Lens takeawayDocument exposure, monitor on the usual schedule, change nothing on the basis of preclinical work.

#### Name the compound, then run the trial

The obvious next step is fractionating the extract to identify which constituents drive the glucose effect, then testing those in a defined preparation. Tetrahydrocannabivarin is one plausible candidate, given that a 2016 randomized trial in type 2 diabetes reported lower fasting plasma glucose and improved beta cell function at 5 mg twice daily.

After that, a human trial with glucose tolerance or hemoglobin A1c as a primary endpoint, in both sexes, with a defined and reproducible preparation. None of that has been done.

Lens takeawayIdentify the constituent, standardize the preparation, then test glucose outcomes in people of both sexes.

#### The research pipeline is the bottleneck

Metabolic cannabinoid research has a cautionary precedent in rimonabant, the CB1 blocker approved in Europe and withdrawn in 2008 over psychiatric adverse effects. The mechanism worked; the drug was not tolerable. That history argues for careful human safety work rather than enthusiasm.

It also argues against treating unregulated retail products as an acceptable substitute for the trials. The gap between a mechanistic finding in mice and a safe human therapy is exactly where regulatory and funding structures matter most.

Lens takeawayA working mechanism is not a safe drug. Rimonabant is the reason that sentence exists.
Related Reading at CED ClinicContinue exploring the evidence[What the Latest Physiology Research Reveals About Cannabis Formulation and Diabetes Risk](https://cedclinic.com/cannabis-extract-vs-thc-metabolic-health/)

Our primary coverage of this study, with the full outcome-by-outcome breakdown and the entourage framing.

[Read the full study coverage](https://cedclinic.com/cannabis-extract-vs-thc-metabolic-health/)[High-THC Cannabis Increased Inflammation Without Improving Insulin Sensitivity](https://cedclinic.com/high-thc-cannabis-increased-inflammation-without-improving-insulin-sensitivity/)

Human data pointing the other direction on THC and metabolic markers, a necessary counterweight to a mouse result.

[See the human counterpoint](https://cedclinic.com/high-thc-cannabis-increased-inflammation-without-improving-insulin-sensitivity/)[Taurine Attenuates Lipid Accumulation via the eCB-CB1 Axis](https://cedclinic.com/taurine-lipid-accumulation-ecb-cb1-axis-obesity/)

Another line of work on CB1 signaling in adipose tissue, useful for seeing how crowded this mechanistic space has become.

[Explore the mechanism](https://cedclinic.com/taurine-lipid-accumulation-ecb-cb1-axis-obesity/)

Join the Conversation

Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/)

## Frequently Asked Questions

Does cannabis affect fat cells?

In this preclinical study it did. Both purified THC and whole cannabis extracts reduced body weight and fat mass in diet-induced obese mice, and both produced anti-adipogenic effects in cultured 3T3-L1 preadipocytes in a concentration-dependent manner. Anti-adipogenic means the compounds interfered with preadipocytes maturing into fat-storing cells. These are mouse and cell-culture results, and no equivalent human trial has been conducted.

What was the main difference between THC and whole cannabis extract?

Glucose handling. Both reduced fat mass and both reversed obesity-associated changes in adipokine expression, though the extracts normalized adipokine expression more effectively. Only the extracts restored glucose clearance in obese mice to the level found in lean mice. THC alone produced fat loss without normalizing glucose control, which means the two outcomes came apart under the same class of drug.

What is the adipoinsular axis?

It is the two-way signaling relationship between fat tissue and the insulin-producing cells of the pancreas. Adipose tissue releases signaling proteins called adipokines, including leptin and adiponectin, that influence insulin secretion, and insulin in turn influences how fat tissue stores energy. In obesity this loop degrades, contributing to insulin resistance and to the progression toward type 2 diabetes.

Should I use cannabis to manage my blood sugar?

No. This was a study in mice and cultured cells, and no human trial has tested a whole-plant cannabis preparation for glucose control. The study also did not identify which compounds produced the effect, so there is no product that can be matched to the finding. Any decision about cannabis in the context of diabetes belongs with a clinician who knows your medications and your labs.

Why do cannabis users tend to have lower obesity rates?

The association is real but unexplained. Le Strat and Le Foll reported in the American Journal of Epidemiology in 2011 that adjusted obesity prevalence across two national US surveys was 22.0% and 25.3% among adults with no past-year cannabis use, versus 14.3% and 17.2% among those using at least three days per week. Cross-sectional surveys cannot establish direction of effect, and several explanations remain plausible.

Is there any human trial on cannabinoids and blood sugar?

One relevant randomized trial exists for a different cannabinoid. Jadoon and colleagues, in Diabetes Care in 2016, randomized 62 adults with non-insulin-treated type 2 diabetes across five arms for 13 weeks. Tetrahydrocannabivarin at 5 mg twice daily lowered fasting plasma glucose by an estimated 1.2 mmol/L and improved a measure of beta cell function. The trial’s own primary endpoint, HDL cholesterol, was not met.

Which compounds in cannabis are responsible for the metabolic effect?

The study did not determine that, and the authors present it as work still to be done. The design established that something other than THC contributed, because extract and purified THC were matched for THC content and produced different glucose results. Identifying the responsible constituents is the necessary next step before any of this can inform a preparation, a dose, or a clinical decision.

What are the main limitations of this research?

Three stand out. The animals were male only, and sex differences in adipose biology and endocannabinoid signaling are well documented. The extract was not chemically specified, so the active ingredient remains unknown. The cell-culture exposures do not correspond to concentrations reached in a person after inhaled or oral dosing. Mouse metabolic findings frequently fail to reproduce in human trials.

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).